EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Mediation of the Association Between APOE Genotype and Cognitive Change Through Alzheimer’s Disease Biomarkers in Patients With Mild Cognitive Impairment

Sangjae Lee iD, Min Heo iD, Yeshin Kim iD, Seongheon Kim iD, Seo-Young Lee iD, Jae-Won Jang iD, Alzheimer’s Disease Neuroimaging Initiative

Dementia and Neurocognitive Disorders · 2026 · 25 (4) · 243

DOI: 10.12779/dnd.2026.25.4.243 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dementia and Neurocognitive Disorders, 2026. Verfasst von Sangjae Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Kangwon National University Hospital, Chuncheon, Korea. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, National Institute on Aging, National Institutes of Health, National Institute of Biomedical Imaging and Bioengineering.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose: Apolipoprotein E (APOE) ε4 is associated with Alzheimer's disease risk and amyloid pathology, but whether cerebrospinal fluid (CSF) Alzheimer's disease biomarkers show statistical indirect effects in its association with longitudinal clinical worsening in mild cognitive impairment (MCI) remains unclear.

Methods

We analyzed 397 participants with MCI from the Alzheimer's Disease Neuroimaging Initiative. The primary analysis used 36-month change in Clinical Dementia Rating-Sum of Boxes (CDR-SB) in the full cohort. APOE ε4 carrier status was the predictor, baseline CSF amyloid beta 1-42 (Aβ42) and phosphorylated tau 181 (p-tau181) were serial mediators, and age, sex, and education were covariates. Secondary analyses were stratified by amyloid status, and 12- and 24-month analyses and APOE ε4 allele-count models were exploratory and sensitivity analyses, respectively. Indirect effects were evaluated using 5,000 percentile bootstrap resamples.

Results

In the full cohort, the total effect of APOE ε4 on 36-month CDR-SB change was significant (estimate, 1.047; 95% bootstrap confidence interval [CI], 0.552 to 1.540), whereas the residual direct effect was not (0.097; 95% CI, -0.447 to 0.636). The Aβ42-specific indirect effect was significant (0.751; 95% CI, 0.474 to 1.035), while the p-tau181-specific (0.068; 95% CI, -0.007 to 0.167) and sequential Aβ42-to-p-tau181 indirect effects (0.131; 95% CI, -0.002 to 0.309) were not. Secondary and allele-count sensitivity analyses were directionally consistent.

Conclusions

Lower CSF Aβ42 showed a significant statistical indirect association between APOE ε4 carrier status and 36-month clinical worsening in MCI. These observational findings do not establish a causal mediating mechanism.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer DiseaseAmyloid Beta-PeptidesApolipoproteins EMild Cognitive ImpairmentTau Proteins

Autor:innen und Institutionen

  • Department of Neurology, Kangwon National University Hospital, Chuncheon, Korea.
  • School of Medicine, Kangwon National University, Chuncheon, Korea.
  • Department of Neurology, Ewha Womans University Seoul Hospital, Ewha Womans University School of Medicine, Seoul, Korea.
  • Department of Neurology, School of Medicine, Kangwon National University, Chuncheon, Korea.
  • Department of Neurology, Myongji Hospital, Hanyang University College of Medicine, Goyang, Korea.
  • Department of Neurology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.

ORCID-Profile: Sangjae Lee, Min Heo, Yeshin Kim, Seongheon Kim, Seo-Young Lee, Jae-Won Jang

Förderung

  • NIA NIH HHS
  • National Institute on Aging, National Institutes of Health
  • National Institute of Biomedical Imaging and Bioengineering
  • Canadian Institutes of Health Research
  • Foundation for the National Institutes of Health

Zitieren

APA

Lee, S., Heo, M., Kim, Y., Kim, S., Lee, S. Y., Jang, J. W., & Alzheimer’s Disease Neuroimaging Initiative (2026). Mediation of the Association Between APOE Genotype and Cognitive Change Through Alzheimer’s Disease Biomarkers in Patients With Mild Cognitive Impairment. Dementia and Neurocognitive Disorders, 25(4), 243. https://doi.org/10.12779/dnd.2026.25.4.243

Vancouver

Lee S, Heo M, Kim Y, Kim S, Lee SY, Jang JW, et al. Mediation of the Association Between APOE Genotype and Cognitive Change Through Alzheimer’s Disease Biomarkers in Patients With Mild Cognitive Impairment. Dementia and Neurocognitive Disorders. 2026;25(4):243. doi:10.12779/dnd.2026.25.4.243

BibTeX
@article{Lee2026,
  author = {Lee, Sangjae and Heo, Min and Kim, Yeshin and Kim, Seongheon and Lee, Seo-Young and Jang, Jae-Won and Alzheimer’s Disease Neuroimaging Initiative, Alzheimer’s Disease Neuroimaging Initiative},
  title = {Mediation of the Association Between APOE Genotype and Cognitive Change Through Alzheimer’s Disease Biomarkers in Patients With Mild Cognitive Impairment},
  journal = {Dementia and Neurocognitive Disorders},
  year = {2026},
  volume = {25},
  number = {4},
  pages = {243},
  doi = {10.12779/dnd.2026.25.4.243}
}
Kostenlos starten →